| Other author/creator | Boname, Morgan L. |
| Other author/creator | Gee, Amanda Wagner. |
| Other author/creator | Wizemann, Theresa M. |
| Other author/creator | Addie, Siobhan. |
| Other author/creator | Beachy, Sarah H. |
| Other author/creator | National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Drug Discovery, Development, and Translation. |
| Other author/creator | National Academies of Sciences, Engineering, and Medicine (U.S.). Roundtable on Genomics and Precision Health. |
| Other author/creator | National Academies of Sciences, Engineering, and Medicine (U.S.). Board on Health Sciences Policy. |
| Other author/creator | National Academies of Sciences, Engineering, and Medicine (U.S.). Health and Medicine Division. |
| Portion of title |
Role of genetics in clinical drug development |
| Contents |
Introduction -- Overarching considerations for implementing successful genetics-enabled drug development -- Case studies in precision drug development -- Integrating genetics into the drug development pathway for complex diseases -- Finding innovative ways to integrate genetic research into the drug development process -- Reflecting back and looking forward: key themes and potential next steps in genetics-enabled drug development -- Appendix A: References -- Appendix B: Statement of task and workshop agenda -- Appendix C: Speaker biographical sketches -- Appendix D: Registered attendees. |
| Review |
"Those involved in the drug development process face challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that enroll participants based on their genetics represent a potentially disruptive change that could improve patient outcomes, reduce costs associated with drug development, and further realize the goals of precision medicine. On March 8, 2017, the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering, and Medicine hosted the workshop Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development. Participants examined successes, challenges, and possible best practices for effectively using genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials across a variety of disease areas. This publication summarizes the presentations and discussions from the workshop"--Publisher's description. |
| General note | On March 8, 2017, the Forum on Drug Discovery, Development, and Translation (the forum) and the Roundtable on Genomics and Precision Health (the roundtable) of the National Academies of Sciences, Engineering, and Medicine (the National Academies) hosted the workshop Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development. |
| Bibliography note | Includes bibliographical references (pages 93-97). |
| Access restriction | Available only to authorized users. |
| Technical details | Mode of access: World Wide Web |
| Genre/form | Electronic books. |
| LCCN | 2017279512 |
| ISBN | 9780309462631 (paperback) |
| ISBN | 0309462630 (paperback) |
